Related Experiment Video
Updated: Jun 22, 2026
Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
High dose cabergoline in management of ovarian hyperstimulation syndrome
Baris Ata1, Ayse Seyhan2, Serbulent Orhaner3
1American Hospital of Istanbul, Assisted Reproduction Unit, Istanbul, Turkey; Soranus IVF Center, Bursa, Turkey.
Objective:
To describe a case of moderate ovarian hyperstimulation syndrome (OHSS) that was treated with high dose cabergoline.
Design:
Case report.
Setting:
Private assisted reproduction center.
Patient(S):
A 29-year-old woman who developed early moderate OHSS despite preventive cabergoline administration (0.5 mg/day) following controlled ovarian hyperstimulation for IVF treatment.
Intervention(S):
Cabergoline dose was increased to 1 mg/day upon diagnosis of OHSS on the second day after oocyte collection and embryo transfer was postponed to the fifth day after oocyte collection.
Main Outcome Measure(S):
Resolution of OHSS and achievement of healthy live birth.
Result(S):
OHSS resolved rapidly despite occurrence of pregnancy and patient delivered a healthy boy at term.
Conclusion(S):
The higher cabergoline dose might have prevented an increase in the severity of OHSS and its prolongation following occurrence of pregnancy. Randomized controlled trials assessing the efficacy and safety of different doses and durations of cabergoline administration in both prophylactic and therapeutic settings are required.
Related Concept Videos
01:30Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses